News
-
Pearl Therapeutics has won a 2012 TiE50 award from the Indus Entrepreneurs (TiE). Pearl was one of ten winners in the life sciences category. Pearl develops inhaled therapies based on its proprietary particle engineering technology.… Read more . . .
-
The US Patent and Trade Office has awarded a second patent, to Aegis Therapeutics for stabilized formulations of parathyroid hormone and parathyroid hormone analogs. The new patent (US Patent No. 8,173,594) covers formulations for both… Read more . . .
-
US Health and Human Services Secretary Kathleen Sebelius has announced a national plan to fight Alzheimer’s disease that includes almost $8 million in funding for research related to an insulin nasal spray for the treatment… Read more . . .
-
Rigel Pharmaceuticals says that it plans to focus its efforts on two inhaled asthma therapies: R343, an inhaled SYK inhibitor and R256, an inhaled IL13 signaling/JAK inhibitor. A Phase 2 clinical study of R343 will… Read more . . .
-
Elevation Pharmaceuticals has announced that a Phase 2b study of its EP-101 glycopyrrolate inhalation solution in patients with moderate to severe COPD demonstrated that EP-101 produced statistically significant improvement in lung function compared to placebo… Read more . . .
-
Insmed Incorporated, which is developing Arikace liposomal amikacin for inhalation, has appointed Donald J. Hayden, Jr. as Executive Chairman of its Board of Directors, effective immediately. He has been serving as Chairman of the board… Read more . . .
-
Data from the Centers for Disease Control and Prevention (CDC) Asthma Call-back Survey show that 18.7 million US adults (8.2 percent) have asthma today out of approximately 29.1 million adults (12.7 percent) who have been… Read more . . .
-
Pulmatrix is presenting two posters at RDD, one titled “Formulation Characterization of a Novel Levofloxacin Pulmonary Dry Powder Drug Delivery Technology,” and the other titled “Development of an iSPERSE Based Platform for the Delivery of… Read more . . .
-
Aptar Pharma is presenting results from a clinical study of patient ability to use its Prohaler DPI at RDD this week. The study, which was conducted by Professor Patrice Diot at the Centre Hospitalier Regional… Read more . . .
-
Liquidia Technologies has announced results from two studies of inhalation formulations created using the company’s PRINT (Particle Replication In Non-Wetting Templates) particle engineering technology. One study, published in the 2012 issue of the Journal of… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.